Sexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Study - Scorecard - MDSpire
Advertisement
Sexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Study
Clinical Scorecard: Erectile Dysfunction in HIV-Positive Males on Dolutegravir-Based Antiretroviral Therapy in Uganda: Findings from a Cross-Sectional Analysis
At a Glance
Category
Detail
Condition
Erectile Dysfunction
Key Mechanisms
Peripheral physical impairment and central neuro-behavioural suppression associated with dolutegravir.
Target Population
Males living with HIV on dolutegravir-based cART.
Care Setting
Outpatient HIV care clinic in central Uganda.
Key Highlights
59% prevalence of erectile dysfunction in males on dolutegravir for >1 day to 6 months.
Reduced sexual desire is time-limited, observed only in the first 6 months.
Dolutegravir is associated with both peripheral and central mechanisms of sexual dysfunction.
Guideline-Based Recommendations
Diagnosis
Utilize dual-instrument phenotyping strategy for assessing sexual dysfunction.
Management
Consider psychosocial factors and comorbidities when evaluating sexual dysfunction.
Monitoring & Follow-up
Monitor sexual health and potential side effects during the first 6 months of dolutegravir therapy.
Risks
Risk of treatment discontinuation due to sexual dysfunction.
Patient & Prescribing Data
Males aged 15 years and older living with HIV.
Dolutegravir-based cART may lead to significant sexual dysfunction, necessitating careful patient counseling.
Clinical Best Practices
Account for sociodemographic, cardiometabolic, and psychiatric factors in sexual dysfunction assessments.
Employ objective data collection methods for treatment duration.
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
